Related Experiment Videos
Borderline-tuberculoid relapse in lepromatous leprosy
B K Girdhar1, A Girdhar, S L Chauhan
1Central JALMA Institute for Leprosy, Tajganj, AGRA, New Delhi.
Leprosy Review
|June 1, 1993
Summary
Long-term dapsone monotherapy can fail, leading to leprosy relapse. Two patients relapsed with borderline-tuberculoid leprosy after remaining smear-negative for over a decade.
Area of Science:
- Dermatology
- Infectious Diseases
- Microbiology
Background:
- Dapsone monotherapy is a common treatment for leprosy.
- Long-term efficacy and potential for relapse require ongoing investigation.
Observation:
- Two patients received prolonged dapsone monotherapy.
- Both patients achieved and maintained smear-negative status for over 10 years.
Findings:
- Despite long-term smear negativity, both patients relapsed.
- The relapsed leprosy was classified as borderline-tuberculoid (BT).
Implications:
- This highlights the risk of leprosy relapse even after extended dapsone treatment.
- Re-evaluation of long-term leprosy treatment strategies may be necessary.